Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Levis
What types of toys have you found to be the most beneficial for learning and fun?
Toys play a big role in a child’s growth, helping with creativity, motor skills, and problem-solving.
Gilteritinib improves survival in R/R FLT3-mutated AML
Patients with relapsed/refractory (R/R) acute myeloid leukaemia (AML) often have poor prognosis and limited succeeding treatment options. In particular, the presence of FMS-like tyrosine kinase 3 (FLT3) gene mutation adversely affects survival outcomes.
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition - Leukemia
Abstract Internal tandem duplication mutations of FLT3 (FLT3/ITD) confer poor prognosis in AML. FLT3 tyrosine kinase inhibitors (TKIs) alone have limited and transient clinical efficacy thus calling for new targets for more effective combination therapy. In a loss-of-function RNAi screen, we identified NOTCH4 as one such potential target whose inhibition proved cytotoxic to AML cells, and also sensitized them to FLT3 inhibition.
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3
1 Internal tandem duplication mutations of FLT3 (FLT3-ITD) are common in AML and confer an increased relapse risk.2 Allogeneic hematopoietic stem cell transplantation (HCT) in first remission is considered the standard of care for these patients when feasible.1,3 Acute myeloid leukemia (AML) is stratified into different molecular subtypes to guide therapy.Internal tandem duplication mutations of) are common in AML and confer an increased relapse risk.Allogeneic hematopoietic stem cell...
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Despite advances in frontline treatment with recently approved therapies for acute myeloid leukemia (AML), most patients experience relapsed/refractory (R/R) disease.1,2 R/R AML has a median overall survival (OS) of 4-7 months with standard chemotherapy approaches,3-7 emphasizing the importance of newly approved targeted therapies and the need for additional treatment options.8-10 CONTEXT Key Objective The FLT3 inhibitor gilteritinib is highly active in advanced, FLT3-mutated (FLT3mut) acute...
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
Abstract Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during consolidation (CTX/ATRA/ATO; n = 148), or with CTX/ATRA (n = 259). Median follow-up for overall survival (OS) was 4.8 years.
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
Abstract An immunosuppressive microenvironment promoting leukemia cell immune escape plays an important role in the pathogenesis of AML. Through its interaction with cereblon, a substrate receptor for the E3 ubiquitin ligase complex, pomalidomide leads to selective ubiquitination of transcription factors Aiolos and Ikaros thereby promoting immune modulation.
FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?
Patients with FLT3 internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) are relatively common on any adult leukemia service. These patients tend to be younger and to have high white blood cell counts at presentation, and they are at high risk of relapse if they achieve a remission.1 Prognosis has improved substantially for these patients in the current era, and cure is now a reasonable expectation that is achieved by more than half of patients.
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Abstract Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets. Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation (FLT3-ITD; approximately 25% of all AML cases).
Clinical Implications of Molecular Markers in Acute Myeloid Leukemia
The recently updated World Health Organization Classification (WHO) of myeloid neoplasms and leukemia reflects the fact that research in the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Gene mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML.
Developing Novel Treatments Using the AML Genome
Today we are speaking with Dr. Mark Levis, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, about acute myeloid leukemia (AML) therapy approaches and new molecular targets for the disease based on genetic analyses of AML. A leukemia expert, Dr. Levis is involved in clinical trials of new agents for AML, and his laboratory focuses on identifying new therapies and understanding the underlying molecular pathways of this leukemia.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack